Steven M Snapinn

List of Publications by Year
in descending order

28 papers	7,539 citations	758635 12 h-index	642321 23 g-index
30 all docs	30 docs citations	30 times ranked	6383 citing authors

#	Article	IF	Citations
1	Effects of Losartan on Renal and Cardiovascular Outcomes in Patients with Type 2 Diabetes and Nephropathy. New England Journal of Medicine, 2001, 345, 861-869.	13.9	6,609
2	Noninferiority trials. , 2000, 1, 19.		215
3	Illustrating the Impact of a Time-Varying Covariate With an Extended Kaplan-Meier Estimator. American Statistician, 2005, 59, 301-307.	0.9	185
4	Responder analyses and the assessment of a clinically relevant treatment effect. Trials, 2007, 8, 31.	0.7	131
5	Assessment of futility in clinical trials. Pharmaceutical Statistics, 2006, 5, 273-281.	0.7	111
6	Alternatives for Discounting in the Analysis of Noninferiority Trials. Journal of Biopharmaceutical Statistics, 2004, 14, 263-273.	0.4	67
7	Preservation of effect and the regulatory approval of new treatments on the basis of nonâ€inferiority trials. Statistics in Medicine, 2008, 27, 382-391.	0.8	39
8	Monitoring clinical trials with a conditional probability stopping rule. Statistics in Medicine, 1992, 11, 659-672.	0.8	35
9	Controlling the type 1 error rate in nonâ€inferiority trials. Statistics in Medicine, 2008, 27, 371-381.	0.8	24
10	Calculation of Sample Size in Survival Trials: The Impact of Informative Noncompliance. Biometrics, 2004, 60, 800-806.	0.8	21
11	Informative noncompliance in endpoint trials. Current Controlled Trials in Cardiovascular Medicine, 2004, 5, 5.	1.5	19
12	The role of the unblinded sponsor statistician. Statistics in Medicine, 2004, 23, 1531-1533.	0.8	16
13	PISC Expert Team White Paper: Toward a Consistent Standard of Evidence When Evaluating the Efficacy of an Experimental Treatment From a Randomized, Active-Controlled Trial. Statistics in Biopharmaceutical Research, 2010, 2, 522-531.	0.6	13
14	Some remaining challenges regarding multiple endpoints in clinical trials. Statistics in Medicine, 2017, 36, 4441-4445.	0.8	12
15	On the clinical meaningfulness of a treatment's effect on a timeâ€toâ€event variable. Statistics in Medicine, 2011, 30, 2341-2348.	0.8	11
16	Indirect comparisons in the comparative efficacy and nonâ€inferiority settings. Pharmaceutical Statistics, 2011, 10, 420-426.	0.7	9
17	Analysis of multiple endpoints in clinical trials: it's time for the designations of primary, secondary and tertiary to go. Pharmaceutical Statistics, 2011, 10, 1-2.	0.7	8
18	The issue of multiplicity in noninferiority studies. Clinical Trials, 2012, 9, 730-735.	0.7	4

#	Article	IF	Citations
19	Sample Size Calculation for Survival Data. , 2003, , 892-898.		3
20	Remaining Challenges in Assessing Non-Inferiority. Therapeutic Innovation and Regulatory Science, 2014, 48, 62-67.	0.8	2
21	Accounting for informative non-compliance with a bivariate exponential model in the design of endpoint trials. Pharmaceutical Statistics, 2005, 4, 173-186.	0.7	1
22	Comment on â€œThe Role of p-Values in Judging the Strength of Evidence and Realistic Replication Expectationsâ€• Statistics in Biopharmaceutical Research, 2021, 13, 40-42.	0.6	1
23	Comment on â€œRobust Design and Analysis of Clinical Trials With Nonproportional Hazards: A Straw Man Guidance From a Cross-Pharma Working Groupâ€• The Test Statistic Should Estimate Some Reasonable Measure of Treatment Benefit. Statistics in Biopharmaceutical Research, 2023, 15, 297-299.	0.6	1
24	Incorporation of Clinical Meaningfulness Into the Analysis of a Continuous Variable: A More Powerful Alternative toÂthe Responder Analysis. Statistics in Biopharmaceutical Research, 2014, 6, 349-355.	0.6	0
25	Comparison of Sample Size Requirements of Randomized and Historically Controlled Trials Based on Calibrated Error Rates. Statistics in Biopharmaceutical Research, 0, , 1-5.	0.6	0
26	Stopping a Trial for Futility: The Cooperative New Scandinavian Enalapril Survival Study II. , 2006, , 302-311.		0
27	Independent Data Monitoring Committees. , 2010, , 21-1-21-9.		0
28	A shrinkage estimator for subgroup analysis without the exchangeability assumption. Journal of Biopharmaceutical Statistics, 2022, , 1-13.	0.4	0